132 related articles for article (PubMed ID: 12458564)
1. Ubiquitin is a possible new predictive marker for the recurrence of human hepatocellular carcinoma.
Shirahashi H; Sakaida I; Terai S; Hironaka K; Kusano N; Okita K
Liver; 2002 Oct; 22(5):413-8. PubMed ID: 12458564
[TBL] [Abstract][Full Text] [Related]
2. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.
Suehiro T; Sugimachi K; Matsumata T; Itasaka H; Taketomi A; Maeda T
Cancer; 1994 May; 73(10):2464-71. PubMed ID: 7513601
[TBL] [Abstract][Full Text] [Related]
3. Abnormal prothrombin: evaluation as a tumour marker and localization in tissues of patients with hepatocellular carcinoma.
Koda T; Yamazaki S; Tamura I; Nakaba H; Takao T; Katayama S; Kurimura O
J Gastroenterol Hepatol; 1993; 8(3):212-6. PubMed ID: 7686054
[TBL] [Abstract][Full Text] [Related]
4. Plasma abnormal prothrombin (PIVKA-II): a new and reliable marker for the detection of hepatocellular carcinoma.
Takikawa Y; Suzuki K; Yamazaki K; Goto T; Madarame T; Miura Y; Yoshida T; Kashiwabara T; Sato S
J Gastroenterol Hepatol; 1992; 7(1):1-6. PubMed ID: 1371940
[TBL] [Abstract][Full Text] [Related]
5. NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II.
Nanashima A; Abo T; Taura N; Shibata H; Ichikawa T; Takagi K; Arai J; Oyama S; Nagayasu T
Anticancer Res; 2013 Jun; 33(6):2689-97. PubMed ID: 23749928
[TBL] [Abstract][Full Text] [Related]
6. Immunolocalisation of PIVKA-II in paraffin-embedded specimens of hepatocellular carcinoma.
Tamano M; Sugaya H; Oguma M; Murohisa T; Tomita Y; Matsumura A; Kojima K; Terano A
Liver; 1999 Oct; 19(5):406-10. PubMed ID: 10533798
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic analysis of stage II-III hepatocellular carcinoma showing early massive recurrence after liver resection.
Yamanaka J; Yamanaka N; Nakasho K; Tanaka T; Ando T; Yasui C; Kuroda N; Takata M; Maeda S; Matsushita K; Uematsu K; Okamoto E
J Gastroenterol Hepatol; 2000 Oct; 15(10):1192-8. PubMed ID: 11106101
[TBL] [Abstract][Full Text] [Related]
8. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
Fujiyama S; Morishita T; Shibata J; Sato T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical studies of PIVKA-II in hepatocellular carcinoma by indirect immunofluorescence.
Kuwahara N; Higashi T; Nouso K; Ito T; Tsuji T
Acta Med Okayama; 1995 Feb; 49(1):19-24. PubMed ID: 7762405
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
[TBL] [Abstract][Full Text] [Related]
11. Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma.
Kim JM; Hyuck C; Kwon D; Joh JW; Lee JH; Paik SW; Park CK
World J Surg; 2013 Jun; 37(6):1371-8. PubMed ID: 23443153
[TBL] [Abstract][Full Text] [Related]
12. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
Tang W; Miki K; Kokudo N; Sugawara Y; Imamura H; Minagawa M; Yuan LW; Ohnishi S; Makuuchi M
Int J Oncol; 2003 May; 22(5):969-75. PubMed ID: 12684661
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
Nakagawa T; Seki T; Shiro T; Wakabayashi M; Imamura M; Itoh T; Tamai T; Nishimura A; Yamashiki N; Matsuzaki K; Sakaida N; Inoue K; Okamura A
Int J Oncol; 1999 Feb; 14(2):281-6. PubMed ID: 9917503
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma.
Kuromatsu R; Tanaka M; Shimauchi Y; Shimada M; Tanikawa K; Watanabe K; Yokoo T
J Gastroenterol; 1997 Aug; 32(4):507-12. PubMed ID: 9250899
[TBL] [Abstract][Full Text] [Related]
15. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
[TBL] [Abstract][Full Text] [Related]
16. Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma.
Suehiro T; Matsumata T; Itasaka H; Taketomi A; Yamamoto K; Sugimachi K
Surgery; 1995 Jun; 117(6):682-91. PubMed ID: 7539944
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness.
Tsujikawa H; Masugi Y; Yamazaki K; Itano O; Kitagawa Y; Sakamoto M
Hum Pathol; 2016 Apr; 50():24-33. PubMed ID: 26997435
[TBL] [Abstract][Full Text] [Related]
19. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.
Fujioka M; Nakashima Y; Nakashima O; Kojiro M
Hepatology; 2001 Dec; 34(6):1128-34. PubMed ID: 11732002
[TBL] [Abstract][Full Text] [Related]
20. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
